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A Genome-wide Association Study Identifies
Three Loci Associated with Mean Platelet Volume
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Mean platelet volume (MPV) is increased inmyocardial and cerebral infarction and is an independent and strong predictor for postevent
morbidity andmortality. We conducted a genome-wide association study (GWAS), the KORA (Kooperative Gesundheitsforschung in der
Region Augsburg) F3 500K study, and found MPV to be strongly associated with three common single-nucleotide polymorphisms
(SNPs): rs7961894 locatedwithin intron 3 ofWDR66 on chromosome 12q24.31, rs12485738 upstream of the ARHGEF3 on chromosome
3p13-p21, and rs2138852 located upstream of TAOK1 on chromosome 17q11.2. We replicated all three SNPs in another GWAS from the
UK and in two population-based samples from Germany. In a combined analysis including 10,048 subjects, the SNPs had p values of
7.24 3 1048 for rs7961894, 3.81 3 1027 for rs12485738, and 7.19 3 1028 for rs2138852. These three quantitative trait loci together
accounted for 4%–5% of the variance in MPV. In-depth sequence analysis ofWDR66 in 382 samples from the extremes revealed 20 new
variants and a haplotype with three coding SNPs and one SNP at the transcription start site associated with MPV (p ¼ 6.8 3 105). In
addition, expression analysis indicated a direct correlation of WDR66 transcripts and MPV. These ﬁndings may not only enhance our
understanding of platelet activation and function, but may also provide a focus for several novel research avenues.Platelets are anucleate blood cells and play an important
role in atherogenesis and atherothrombosis, two key
processes underlying cardiovascular disease.1,2 MPV is
increased in myocardial (MIM 608446, MIM 608557) and
cerebral (MIM 601367, MIM 606799) infarction and is an
independent and strong predictor for postevent morbidity
and mortality.3,4 Platelets are formed from polyploid bone
marrow precursor cells, the megakaryocytes, through a
process of proplatelet formation. The volume of platelets
is tightly regulated but the precise molecular machinery
that controls it is only partially understood and involves
outside-in signals emanating from extracellular matrix
proteins and growth factors.5
There is ample evidence that the blood cell indices under
which is also MPV have a high level of heritability. In twin
studies, heritability estimates for hemoglobin levels and
the counts of white blood cells and platelets ranged from
0.37 to 0.89.6 Studies in baboons and rodents conﬁrmed
these ﬁndings and found (not surprisingly) that also the
volumes of red cells and platelets are under genetic
control.7
We conducted a genome-wide association study (GWAS)
in individuals sampled from the KORA (Kooperative Ge-
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cruited from the MONICA S3 survey, a population-based
sample from the general population living in the region of
Augsburg, Southern Germany, which was carried out in
1994/95. The standardized examinations applied in this
survey including 4856 participants aged 25 to 74 years
(response 75%) have been described in detail elsewhere.8,9
In a follow-up examination of S3 in 2004/05 (KORA F3),
3006 subjects participated. For KORA F3 500K we selected
1644 subjects of these participants then aged 35 to 79 years,
including 1606 individuals with MPV values available.
Genotyping was performed with the Affymetrix Gene
Chip Human Mapping 500K Array Set as described in
Do¨ring et al.10 In brief, on SNP level from a total of
500,568 SNPs, we excluded for the purpose of this analysis
all SNPs on chromosome X, leaving 490,032 autosomal
SNPs for the GWA screening step. The X chromosome
SNPs were excluded from the analysis because the X chro-
mosome has to be treated differently from the autosomes
(note that the Affymetrix Chip used does not assay the Y
chromosome). Because most loci on the X chromosome
are subject toX chromosome inactivation, it cannot be pre-
dicted which allele is active. Furthermore, because there is
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power are different from the autosomes. From the 490,032
autosomal SNPs, 335,152 (68.39%) SNPs passed all quality
control criteria andwere selected for the subsequent associ-
ation analyses. Criteria leading to exclusion were genotyp-
ing efﬁciency <95% (N ¼ 49,325) and minor allele
frequency (MAF) <5% (N ¼ 101,323). An exact Fisher test
has been used to detect deviations from Hardy-Weinberg
equilibrium, and we excluded all SNPs with p values below
105 (N ¼ 4,232) after passing the other criteria.10
We used three independent samples for replication. The
ﬁrst was a GWAS sample from the UK National Blood
Services collection of Common Controls (UKBS-CC) typed
with the same Affymetrix Chip. Details of genotyping and
quality criteria are given in the original study.11 In brief,
the UKBS-CC collection is an anonymized collection of
DNA samples from 3100 healthy blood donors. The collec-
tion has been established by the three British blood services
of England, Scotland, and Wales as part of the Wellcome
Trust Case Control Consortium (WTCCC) study.11 Data
from 1203 English individuals of panel 1 (UKBS-CC1) with
availablegenotypeswereused in this study,becausenoMPV
data were available for the Scottish and Welsh samples.
The second replication cohort was recruited from the
KORA S4 survey, an independent population-based sample
fromthegeneralpopulation living in the regionofAugsburg,
SouthernGermany, conducted in 1999/2001. The standard-
ized examinations applied in the survey (4261 participants,
response 67%) have been described in detail elsewhere.8,10
Genotyping of SNPs was performed with the iPLEX (Seque-
nom, San Diego, CA) method by means of matrix-assisted
laser desorption ionization-time of ﬂight mass spectrom-
etry method (MALDI-TOF MS, Mass Array, Sequenom) ac-
cording to themanufacturer’s instructions. Details of geno-
typing and quality criteria are given elsewhere.10
The third replication sample, the Study of Health in
Pomerania (SHIP), is a cross-sectional population-based
health survey conducted between 1997 and 2001 in West
Pomerania, a region in the northeastern part of Germany.
The detailed objectives and the study design have been
published elsewhere.12 The ﬁnal SHIP population
comprising 4310 participants (response 68.8%) was
invited to attend a 5-year follow-up examination, termed
SHIP1, which was conducted between 2002 and 2006
(3300 participants; response 76.6%). For replication anal-
ysis, the SHIP1 population was included. The SNPs were
genotyped with custom-made 50 nuclease allelic discrimi-
nation (Taqman) assays (AppliedBiosystems, Foster City,
CA). Quality control included the independent replication
of 3% of genotypes and the inclusion of 2% negative
controls on all DNA sample plates.
In all samples, MPVwasmeasured on fresh venous EDTA
blood with an automatic analyzer (Coulter STKS in KORA
F3, KORA S4, and UKBS-CC1 and Sysmex SE-9000 analyzer
in SHIP; referenceMPV values were 7.8–11.0 ﬂ in KORA F3,
KORA S4, and UKBS-CC1 and 9.0–12.5 ﬂ in SHIP).
A description of the GWA study population and the
replication samples is given in Table S1 available online.The AIn all studies, informed consent was obtained from
participants and the studies were approved by the local
ethical committees.
We used additive genetic models assuming a trend per
copy of the minor allele to test the association of MPV
values and genotypes. MPV values were natural log trans-
formed before analysis to approximate the normal distribu-
tion. All models were adjusted for age and gender, and
additionally for collection center within the UK sample.
We used linear regression algorithms as implemented in
the statistical analysis packages R (KORA F3 500K), PLINK13
(KORAF3500K,UKBS-CC1), and SAS version 9.1 (KORAS4,
SHIP). Imputation of genotypes in KORA F3 500K used to
ﬁne-map the replicated regions in Figures 1B–1D was
performed with the software MACH based on HapMap II.
Meta-analysis statistics were obtained with a weighted
z-statistics method, where weights were proportional to
the square root of the number of individuals examined in
each sample and selected such that the squared weights
sum was 1. Calculations were implemented in the METAL
package. Combined betas and SEs were calculated with
Inverse Variance meta-analysis, together with Cochran’s
Q and I2 with R scripts.
To select signiﬁcant SNPs in the genome-wide screening
and in the replication studies, we used conservative Bonfer-
roni thresholds that corresponded to an uncorrected signif-
icance level of 0.05. The associatedquantile-quantile plot in
Figure S1 shows good agreement with the null distribution.
TheGWAS identiﬁed several genomic locations as poten-
tially associatedwithMPV (Figure 1A). Of the 335,152 SNPs
tested by regression analysis, 10 representing 8 distinct
genetic regions reached p values below105 (Table 1; Tables
S2 and S3). One SNP rs7961894 (p ¼ 2.093 1011; Table 1;
Figure 1B), located within intron 3 of the WDR66 (WD
repeat domain 66) gene at 12q24.31, reached genome-
wide signiﬁcance with a Bonferroni corrected signiﬁcance
level of 1.53 107. The 10 SNPswere taken forward to repli-
cate them in the UKBS-CC1 GWAS sample, and at the same
time 8 SNPs (representing 8 different loci) were taken
forward for replication in the KORA S4 Study. One of those
SNPs could not be replicated in KORA S4 because of
problems with the assay design (Table S3). The SNPs,
which were successfully replicated in both studies, were
rs7961894 inWDR66, rs12485738on30 and56 kbdistance
fromthe transcription start sites of two short isoformsof the
ARHGEF3 gene at 3p13-p21 (Rho guanine nucleotide
exchange factor 3) (MIM612115), and rs2138852 upstream
of the TAOK1 gene at 17q11.2 (TAO Kinase 1; Figures 1B–
1D; Table 1) (MIM 610266). None of the other tested SNPs
reached signiﬁcance in the UKBS-CC1 or KORA S4 sample
given a corrected signiﬁcance of 0.005 (Table S3). Finally,
only the three loci that have been successfully replicated
in both studies were taken forward to additional replication
in the SHIP study where these SNPs again showed a signiﬁ-
cant association with MPV values (Table 1).
In further analysis in the GWA population, it was exam-
ined whether the three lead SNPs are associated with othermerican Journal of Human Genetics 84, 66–71, January 9, 2009 67
Figure 1. Summary of Genome-wide Association and Replication Results
(A) Genome-wide association study for log-transformed MPV on a population-based sample of 1606 individuals from the KORA F3 500K
study. The x axis represents the genomic position (in Gb) of 335,152 SNPs; the y axis shows log10(P). The horizontal line indicates the
threshold for genome-wide significance at 1.5 3 107. After correcting for multiple testing, we found that one SNP on chromosome 12
attained genome-wide statistical significance.
(B–D) p value plots showing the association signals in the region of WDR66 on chromosome 12 (B), ARHGEF3 on chromosome 3 (C), and
TAOK1 on chromosome 17 (D). log10 p values are plotted as a function of genomic position (NCBI Build 36). Large diamonds indicate
the p value for the lead SNP in KORA F3 500K (red), KORA S4 (blue), UKBS-CC1 (green), and SHIP (magenta). Proxies are indicated with
diamonds for genotyped SNPs and circles for imputed SNPs of smaller size, with colors determined from their pairwise r2 values from
KORA F3 500K. Red diamonds indicate high LD with the lead SNP (r2 > 0.8), orange diamonds indicate moderate LD with the lead
SNP (0.5 < r2 < 0.8), yellow indicates markers in weak LD with the lead SNP (0.2 < r2 < 0.5), and white indicates no LD with the lead
SNP (r2 < 0.2). Recombination rate estimates (HapMap Phase II) are given in light blue, Refseq genes (NCBI) are displayed by green bars.traits, such as white blood cell count, red blood cell count,
mean corpuscular volume, hematocrit, and hemoglobin.
None of the lead SNPs showed a signiﬁcant association
(p < 0.05) with any of these traits (data not shown).
In the combined sample of 10,048 individuals, the SNP
rs7961894 reached a p value of 7.24 3 1048 (effect per
minor allele copy ¼ 0.032 per log ﬂ, CI 0.028–0.037), the68 The American Journal of Human Genetics 84, 66–71, January 9, 20SNP rs12485738 a p value of 3.813 1027 (effect per minor
allele copy ¼ 0.015 per log ﬂ, CI 0.012–0.017), and the
third SNP (rs2138852) a combined p value of 7.19 3
1028 (effect per minor allele copy ¼ 0.015 per log ﬂ,
CI 0.018–0.013).
The reference values were about 15%higher in SHIP than
in the other studies,which is best explained by the different09
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KORA 500K F3 A G 98.6 0.706 1,584 (36.03) 0.019 (0.0038) 8.57 3 107 1.52%
UKBS-CC1 99.9 0.449 1,219 (36.30) 0.017 (0.0043) 5.61 3 105 1.27%
KORA S4 94.8 2.2 3 1016a 4,137 (30.14) 0.015 (0.0022) 4.02 3 1013 1.11%
SHIP 96.2 0.2922 3,024 (36.97) 0.012 (0.0024) 6.31 3 107 0.87%
Combinedb 9,964 0.015 (0.0014) 3.81 3 1027
rs7961894 12 120849966
KORA 500K F3 A G 99.7 0.013 1,602 (11.92) 0.040 (0.0059) 2.09 3 1011 2.77%
UKBS-CC1 100.0 0.685 1,220 (11.32) 0.033 (0.0063) 3.04 3 107 1.90%
KORA S4 97.9 0.937 4,070 (11.18) 0.034 (0.0037) 7.26 3 1020 2.04%
SHIP 98.2 0.3628 3,142 (11.14) 0.028 (0.0036) 2.61 3 1014 1.84%
Combinedb 10,034 0.032 (0.0022) 7.24 3 1048c
rs2138852 17 24727475
KORA 500K F3 C T 99.9 1.000 1,605 (49.33) 0.017 (0.0037) 3.31 3 106 1.34%
UKBS-CC1 99.5 0.307 1,220 (47.80) 0.018 (0.0041) 1.62 3 105 1.38%
KORA S4 99.8 0.5329 4,139 (47.17) 0.018 (0.0023) 1.57 3 1014 1.42%
SHIP 96.2 0.1123 3,084 (48.21) 0.011 (0.0024) 1.70 3 106 0.74%
Combinedb 10,048 0.015 (0.0014) 7.19 3 1028
Effect sizes (estimates and SE) are given for each copy of the minor allele and are expressed as natural logarithm of MPV.
a Violation of HWE equilibrium, also after regenotyping.
b No study heterogeneity (I2 range 0–43, p values > 0.05).
c The p value excluding the KORA S4 sample (n ¼ 5964) is 1.087 3 1029.analysis platforms with the Coulter-method (KORA, UKBS-
CC1) or light scatter analysis (Sysmex SE-9000, SHIP).
However, this fact may be negligible for the analysis,
provided that the values are not differentially variable
over the range. An internal comparison of the methods
carried out in the SHIP project resulted in the regression
equation Y (ﬂ Sysmex SE-9000) ¼ 1.000*X (ﬂ Coulter-
method) þ 1.850, indicating that all values are shifted by
the constant value of 1.850 upwards. We carried out an
analysis corrected with MPV values for SHIP and found
rather higher effect estimates for all three SNPs.We decided
to use the conservative uncorrected values resulting in
a slight underestimation of the effects.
Because the lead SNP inWDR66 reached the best p value
and accounted for about 2.0% of the MPV variance, we
decided to analyze the coding sequence of WDR66 in
more detail (Tables S4 and S5). High-resolution melting
analysis was used as mutation scanning technology to
analyze the coding region of WDR66. WDR66 exons were
PCR ampliﬁed with intronic primers with ~5 ng genomic
DNA with a ﬁnal denaturation step at 94C for 1 min
(0.25 units Thermo-Start Taq DNA polymerase [Abgene],
13 LCGreen Plus [BIOKE], 0.25 mM of each primer; Table
S5). High-resolution melting analysis was performed on
a LightScanner instrument (IdahoTechnology). In the pres-
ence of the saturating double-stranded DNA-binding dye,
amplicons were slowly heated from 77C until fully dena-
tured (96C)while theﬂuorescencewasmonitored.Melting
curves were analyzed by LightScanner software (Idaho
Technology), with normalized, temperature-shifted curvesThe Adisplayed as difference plots (dF/dT). Detected samples
with altered melting curves compared with the average of
multiple wild-types were directly sequenced with a BigDye
Cycle sequencing kit (Applied Biosystems).
We analyzed the sequence of all 21 coding exons and the
50 UTR in 382 samples selected from the high and low
extremes of the MPV distribution in 4000 individuals
(KORA S4). We found variants or variation in 4 of the 9
coding SNPs, which were already annotated in dbSNP.
None of these showed an association with MPV, but the
A allele of the lead SNP rs7961894 was overrepresented
in the high-MPV group (p ¼ 1.3 3 106, Fisher’s exact test
for allele distribution, Figure 2; more detailed information
in Table S4). In addition, we detected 10 nonsynonymous
SNPs, one nonsense and ﬁve synonymous variants, a 15 bp
and an 18 bp insertion, one 30 UTR SNP and one SNP (C/
T) a single bp upstream of the UCSC annotated 50 end of
the WDR66 transcript (see Table S4). The latter variant
(ss107795092) with a minor allele frequency (MAF) of
3.6% falls within a conserved region (LOD ¼ 24, phast-
Cons program) and is signiﬁcantly overrepresented in the
low-MPV group (p ¼ 6.8 3 105). This variant is linked
(r2 > 0.9, see Table S6) with three other newly discovered
coding SNPs (ss107795081-3, p.C304C, p.V307I, and
p.R417Q) and they deﬁne—in the background of the G
allele of the lead SNP rs7961894—a rare haplotype (MAF
2.5%). This haplotype may contribute to the signiﬁcant
association of rs7961894 with MPV, but the strongest
association was found for the lead SNP followed by
ss107795092 alone.merican Journal of Human Genetics 84, 66–71, January 9, 2009 69
Figure 2. Localization of MPV-Associated SNPs within the 50
Part of the WDR66 Gene
The p values given are based on Fisher’s exact test in 382 samples
from the most extreme (high and low) MPV distribution in KORA S4.
Figure 3. Expression Analysis of WDR66 and Association with
Log MPV
WDR66 expression was analyzed via whole-blood genome-wide
transcription profiling in a subgroup of 323 KORA F3 samples
with Illumina Human-6 v2 Expression BeadChip (probe ID
2630343).The strong correlation of the SNP prompted us to investi-
gate the transcript levels ofWDR66 in a randomly selected
subgroup of 323 KORA F3 samples with whole-genome
expression proﬁles available. Gene-expression analysis
was performed with the Illumina Human-6 v2 Expression
BeadChip as described in Do¨ring et al.10 In brief, blood
samples were collected under fasting conditions in PAX-
gene (TM) Blood RNA tubes (PreAnalytiX) and RNA extrac-
tion was performed with the PAXgene Blood RNA Kit
(QIAGEN). RNA was reverse transcribed and biotin-UTP
labeled with the Illumina TotalPrep RNA Ampliﬁcation Kit
(Ambion). The raw data were exported from the Illumina
‘‘Beadstudio’’ Software to R, converted into logarithmic
scores, and normalized.10 We observed no association
between intronic lead SNP rs7961894 and WDR66 tran-
script level, but a signiﬁcant association of the levels of
the WDR66 transcript with MPV (p ¼ 0.01, Figure 3) via
the linear regressionmodel. In addition, we looked at corre-
lationbetweengene expression and genotypes for the other
two lead SNPs and found no signiﬁcant association. Based
on the small samples size for the expression studies, the
analysis has a limited power. However, the lacking associa-
tion between the intronic SNP andWDR expression argues
against a direct effect on WDR66 expression. On the other
side, the correlation of WDR66 expression with MPV
supports the hypothesis that WDR66 is involved in the
determination of MPV.
In summary,we identiﬁed three loci associatedwithMPV,
a quantitative trait that is increasingly recognized as being
associated with the post-MI event risk of major complica-
tions. These three loci accounted for about 5% of the vari-
ance in MPV values in the normal population. All three
genes are plausible biological candidates that could modify
the process of platelet formation. The process of proplatelet
formation is critically dependent on reorganization of cyto-
skeletal components and localized apoptosis seems to play
an important role.5,14 WD-repeat proteins are present in
all eukaryotes but not in prokaryotes. It is hypothesized
that they are involved in the regulationof cellular functions
ranging from signal transduction and transcription regula-
tion to cell-cycle control and apoptosis.15 Our expression
experiment indicates a direct correlation of WDR66 tran-70 The American Journal of Human Genetics 84, 66–71, January 9, 20script level and MPV. Previous studies have shown that
ARHGEF3 (XPLN), which encodes the rho guanine-nucleo-
tide exchange factor 3 (RhoGEF3), is expressed in the brain,
skeletal muscle, heart, kidney, and platelets as well as
macrophage and neuronal cell tissues.16 RhoGEFs activate
RhoGTPases,whichplay an important role inmany cellular
processes such as regulation of cell morphology, cell aggre-
gation, cytoskeletal rearrangements, and transcriptional
activation.17
TAOK1, which is expressed in a wide variety of different
tissues that include brain, heart, lung, testis, skeletal
muscle, placenta, thymus, prostate, and spleen, encodes
the TAO kinase 1 peptide (hTAOK1 also known as MARKK
or PSK2) a microtubule afﬁnity-regulating kinase that has
been identiﬁed recently as an important regulatorofmitotic
progression, required for both chromosome congression
and checkpoint-induced anaphase delay.18 TAOK1 acti-
vates c-Jun N-terminal kinase (JNK) and induces apoptotic
morphological changes that include cell contraction,
membrane blebbing, and apoptotic body formation.19
In conclusion, to our knowledge we identiﬁed the ﬁrst
three quantitative trait loci associated with MPV in the
general population. Identiﬁcation of primary genetic deter-
minants of MPVmay not only enhance our understanding
of platelet activation and function, but may also provide
a focus for several novel research avenues.Supplemental Data
Supplemental Data include one ﬁgure and six tables and can be
found with this article online at http://www.ajhg.org/.09
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